NVIDIA, Novo Nordisk, DCAI Forge AI Drug Discovery Partnership

NVIDIA has announced a strategic collaboration with Novo Nordisk and DCAI (Danish Centre for AI Innovation) to advance drug discovery using AI-driven computational platforms. The partnership centers on Novo Nordisk’s use of DCAI’s Gefion sovereign AI supercomputer, powered by NVIDIA DGX SuperPOD, to accelerate pharmaceutical research through generative AI models, physical simulations, and biomedical language models.

The collaboration enables Novo Nordisk to deploy NVIDIA BioNeMo for generative drug discovery, NVIDIA NIM and NeMo microservices for custom agentic workflows, and NVIDIA Omniverse for physics-based simulation environments. This infrastructure supports research into single-cell models predicting cellular responses to drug candidates, molecular design for drug-like properties, and biomedical large language models analyzing correlations between genes, proteins, and diseases.

“AI is essential for every industry, and there’s no other field that will benefit more from acceleration than drug discovery,” said Rory Kelleher, senior director of business development for life sciences at NVIDIA, in the official announcement. “Working with Novo Nordisk, we’re advancing critical R&D applications with fundamental tools that can harness the full potential of generative and agentic AI.”

Novo Nordisk’s senior vice president of AI and digital innovation, Mishal Patel, emphasized the partnership’s strategic value: “By coupling NVIDIA’s accelerated computing platform with Novo Nordisk’s deep expertise in life sciences, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently. Gefion will allow us to run experiments at an unprecedented scale.”

DCAI, which owns and operates Gefion—the flagship AI supercomputer in Denmark—positions this as a catalyst for national healthcare innovation. Nadia Carlsten, CEO of DCAI, stated: “With Gefion’s computational power, we can tackle the toughest R&D challenges, with the ultimate goal of unlocking new possibilities for pharmaceutical research and development.”

The partnership builds on NVIDIA’s broader healthcare AI ecosystem, including the BioNeMo platform and open-source models like Proteina-Complexa for protein drug discovery. Novo Nordisk joins other healthcare adopters of NVIDIA’s open models, such as Viva Biotech and Manifold Bio, as noted in NVIDIA’s March 2026 investor update.

Gefion’s capabilities extend beyond Novo Nordisk: Danish startup Teton uses the supercomputer to develop AI care companions for hospitals, reducing nurse workloads by 25% in early trials. Another pharma client leverages Gefion for neurological disorder drug discovery, while a venture-backed firm accelerates oral alternatives to biologics targeting previously undruggable proteins.

This collaboration underscores a strategic shift in pharmaceutical R&D, where AI-driven approaches aim to compress the traditional 10–15 year drug development timeline. By integrating NVIDIA’s AI infrastructure with Novo Nordisk’s scientific expertise, the partnership targets two critical bottlenecks: molecular design complexity and data analysis of biomedical literature.

For Denmark, the initiative aligns with national goals to position the country as a hub for AI-driven healthcare innovation. DCAI’s role in lowering barriers to advanced computing access enables broader adoption across Danish healthcare and biotech sectors, as highlighted in the company’s public statements.

The partnership reflects NVIDIA’s growing focus on domain-specific AI platforms, moving beyond general-purpose models to specialized solutions for life sciences. This approach contrasts with competitors’ broader AI strategies, emphasizing tailored infrastructure for high-stakes industries like pharmaceuticals.

Artūras Malašauskas is an AI Systems Integrator with 20+ years of production-grade web engineering experience. He has designed, shipped, and scaled enterprise Python/PHP systems for logistics, SaaS, and public-sector clients. For the past year, he has focused exclusively on AI integrations: deploying open-source LLMs, building generative media pipelines (image, audio, video), and engineering multi-agent workflows for real production environments. His standard: reproducibility, security, cost-efficient inference—no vaporware. He documents and evaluates emerging AI tooling, separating verified capabilities from marketing noise. Technical editor at: muza-ai.eu, ai-verslas.lt, ai-naujinos.lt Connect on LinkedIn